ROC Plotter showed that NR1H3 was upregulated in responders of luminal A (AUC = 0.564, p = 2.9e-02) and grade 1 subtype breast cancer patients with Tamoxifen treatment (AUC = 0.822, p = 1.1e-05) based on relapse-free survival (RFS) at 5 years (Supplementary Figure S14A). This evidence concerns the gene NR1H3 and breast cancer.